With the addition of pTau217 as a stand-alone test, Labcorp's portfolio of Alzheimer's tests has advanced significantly, enhancing its current range of blood-based biomarker testing. More on the ...

"It is currently unclear how useful the Labcorp test will be in accurately ... patient predicted to have preeclampsia from a blood test early in pregnancy as opposed to clinical factors," Zahn ...

Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth ...

The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw. Labcorp Plasma Complete detects ...

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood ...

The test, which utilizes circulating tumor DNA (ctDNA) from a blood draw, is intended to help oncologists tailor personalized treatment plans. According to InvestingPro analysis, Labcorp maintains ...

The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw. "Labcorp Plasma Complete delivers ...

Targeted Development in High-Growth Areas: In 2024, Labcorp enhanced its neurodegenerative diseases testing capabilities with two blood-based biomarkers — the pTau217 test for Alzheimer's ...